Abstract

Thyroid cancer is common, yet the sequence of alterations that promote tumor formation are incompletely understood. Here we describe a novel model of thyroid carcinoma in zebrafish that reveals temporal changes due to BRAFV600E. Through the use of real-time in vivo imaging we observe disruption in thyroid follicle structure that occurs early in thyroid development. Combinatorial treatment using BRAF and MEK inhibitors reversed the developmental effects induced by BRAFV600E. Adult zebrafish expressing BRAFV600E in thyrocytes developed invasive carcinoma. We identified a gene expression signature from zebrafish thyroid cancer that is predictive of disease free survival in patients with papillary thyroid cancer. Gene expression studies nominated TWIST2 as a key effector downstream of BRAF. Using CRISPR/Cas9 to genetically inactivate a TWIST2 orthologue, we suppressed the effects of BRAFV600E and restored thyroid morphology and hormone synthesis. These data suggest that expression of TWIST2 plays a role in an early step of BRAFV600E-mediated transformation.

Data availability

The following previously published data sets were used

Article and author information

Author details

  1. Viviana Anelli

    Department of Surgery, Weill Cornell Medical College, New York, United States
    Competing interests
    The authors declare that no competing interests exist.
  2. Jacques A Villefranc

    Department of Surgery, Weill Cornell Medical College, New York, United States
    Competing interests
    The authors declare that no competing interests exist.
  3. Sagar Chhangawala

    Department of Surgery, Weill Cornell Medical College, New York, United States
    Competing interests
    The authors declare that no competing interests exist.
  4. Raul Martinez-McFaline

    Department of Surgery, Weill Cornell Medical College, New York, United States
    Competing interests
    The authors declare that no competing interests exist.
  5. Eleonora Riva

    Section of Endocrinology, Department of Medical Science, University of Ferrara, Ferrara, Italy
    Competing interests
    The authors declare that no competing interests exist.
  6. Anvy Nguyen

    Department of Surgery, Weill Cornell Medical College, New York, United States
    Competing interests
    The authors declare that no competing interests exist.
  7. Akanksha Verma

    Institute for Computational Biomedicine, Weill Cornell Medical College, New York, United States
    Competing interests
    The authors declare that no competing interests exist.
  8. Rohan Bareja

    Institute for Computational Biomedicine, Weill Cornell Medical College, New York, United States
    Competing interests
    The authors declare that no competing interests exist.
  9. Zhengming Chen

    Department of Healthcare Policy and Research, Weill Cornell Medical College, New York, United States
    Competing interests
    The authors declare that no competing interests exist.
  10. Theresa Scognamiglio

    Department of Pathology and Laboratory Medicine, Weill Cornell Medical College, New York, United States
    Competing interests
    The authors declare that no competing interests exist.
  11. Olivier Elemento

    Institute for Computational Biomedicine, Weill Cornell Medical College, New York, United States
    Competing interests
    The authors declare that no competing interests exist.
  12. Yariv Houvras

    Department of Surgery, Weill Cornell Medical College, New York, United States
    For correspondence
    yah9014@med.cornell.edu
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0003-0751-3215

Funding

National Institutes of Health (R21CA20254001)

  • Yariv Houvras

National Institutes of Health (T32GM007739)

  • Raul Martinez-McFaline

National Institutes of Health (P50-CA172012)

  • Jacques A Villefranc

The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.

Ethics

Animal experimentation: This study was performed in strict accordance with the recommendations in the Guide for the Care and Use of Laboratory Animals of the National Institutes of Health. All of the animals were handled according to approved institutional animal care and use committee (IACUC) protocols (#2011-0026) of Weill Cornell Medical College.

Copyright

© 2017, Anelli et al.

This article is distributed under the terms of the Creative Commons Attribution License permitting unrestricted use and redistribution provided that the original author and source are credited.

Metrics

  • 2,256
    views
  • 445
    downloads
  • 52
    citations

Views, downloads and citations are aggregated across all versions of this paper published by eLife.

Download links

A two-part list of links to download the article, or parts of the article, in various formats.

Downloads (link to download the article as PDF)

Open citations (links to open the citations from this article in various online reference manager services)

Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)

  1. Viviana Anelli
  2. Jacques A Villefranc
  3. Sagar Chhangawala
  4. Raul Martinez-McFaline
  5. Eleonora Riva
  6. Anvy Nguyen
  7. Akanksha Verma
  8. Rohan Bareja
  9. Zhengming Chen
  10. Theresa Scognamiglio
  11. Olivier Elemento
  12. Yariv Houvras
(2017)
Oncogenic BRAF disrupts thyroid morphogenesis and function via Twist expression
eLife 6:e20728.
https://doi.org/10.7554/eLife.20728

Share this article

https://doi.org/10.7554/eLife.20728

Further reading

    1. Cancer Biology
    2. Evolutionary Biology
    Arman Angaji, Michel Owusu ... Johannes Berg
    Research Article

    In growing cell populations such as tumours, mutations can serve as markers that allow tracking the past evolution from current samples. The genomic analyses of bulk samples and samples from multiple regions have shed light on the evolutionary forces acting on tumours. However, little is known empirically on the spatio-temporal dynamics of tumour evolution. Here, we leverage published data from resected hepatocellular carcinomas, each with several hundred samples taken in two and three dimensions. Using spatial metrics of evolution, we find that tumour cells grow predominantly uniformly within the tumour volume instead of at the surface. We determine how mutations and cells are dispersed throughout the tumour and how cell death contributes to the overall tumour growth. Our methods shed light on the early evolution of tumours in vivo and can be applied to high-resolution data in the emerging field of spatial biology.

    1. Cancer Biology
    2. Evolutionary Biology
    Susanne Tilk, Judith Frydman ... Dmitri A Petrov
    Research Article

    In asexual populations that don’t undergo recombination, such as cancer, deleterious mutations are expected to accrue readily due to genome-wide linkage between mutations. Despite this mutational load of often thousands of deleterious mutations, many tumors thrive. How tumors survive the damaging consequences of this mutational load is not well understood. Here, we investigate the functional consequences of mutational load in 10,295 human tumors by quantifying their phenotypic response through changes in gene expression. Using a generalized linear mixed model (GLMM), we find that high mutational load tumors up-regulate proteostasis machinery related to the mitigation and prevention of protein misfolding. We replicate these expression responses in cancer cell lines and show that the viability in high mutational load cancer cells is strongly dependent on complexes that degrade and refold proteins. This indicates that the upregulation of proteostasis machinery is causally important for high mutational burden tumors and uncovers new therapeutic vulnerabilities.